Agennix's talactoferrin misses Phase III NSCLC endpoint

Agennix AG (Xetra:AGX) said twice-daily oral talactoferrin plus best supportive care missed the primary endpoint of median overall survival (OS) vs. placebo plus best

Read the full 242 word article

How to gain access

Continue reading with a
two-week free trial.